Inmunoterapia en Primera Linea. Avanzando en el tratamiento del CPNM

17 / 42

• Durable survival was observed in all PD-L1 subgroups
Overall Survival – PD-L1 Subgroups
Carcereny et al., BIRCH. WCLC 2017 17
Median duration of survival follow-up = 34.3 months